SpyGlass Pharma, Inc. (SGP) - Total Liabilities
Based on the latest financial reports, SpyGlass Pharma, Inc. (SGP) has total liabilities worth $11.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See SGP days of operational coverage to measure how many days the company can operate on defensive assets alone.
SpyGlass Pharma, Inc. - Total Liabilities Trend (2023–2025)
This chart illustrates how SpyGlass Pharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check SpyGlass Pharma, Inc. (SGP) asset resilience to evaluate the company's liquid asset resilience ratio.
SpyGlass Pharma, Inc. Competitors by Total Liabilities
The table below lists competitors of SpyGlass Pharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Embracer Group AB Series B
LSE:0GFE
|
UK | Skr7.27 Billion |
|
Si-Bone Inc
NASDAQ:SIBN
|
USA | $66.41 Million |
|
Shanghai Ganglian E Commerce
SHE:300226
|
China | CN¥18.76 Billion |
|
Jiangsu Huachang Chemical Co Ltd
SHE:002274
|
China | CN¥2.48 Billion |
|
Logwin AG
XETRA:TGHN
|
Germany | €384.45 Million |
|
Shandong Jinjing Science and Technology Stock Co Ltd
SHG:600586
|
China | CN¥3.88 Billion |
|
Capital City Bank Group
NASDAQ:CCBG
|
USA | $3.88 Billion |
|
Decai Decoration Co Ltd
SHG:605287
|
China | CN¥9.13 Billion |
Liability Composition Analysis (2023–2025)
This chart breaks down SpyGlass Pharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of SpyGlass Pharma, Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 25.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SpyGlass Pharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual total liabilities of SpyGlass Pharma, Inc. from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $214.70 Million | +156.23% |
| 2024-12-31 | $83.79 Million | +13.03% |
| 2023-12-31 | $74.13 Million | -- |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more